Long‐Term Effect of Microwave Ablation on Patients Undergoing Hemodialysis for Moderate Secondary Hyperparathyroidism: A Retrospective Cohort Study. (23rd January 2021)

• Record Type: Journal Article
• Authors: Li, Dishan; Wang, Gang; Chen, Xinpan; Guo, Wang; Huang, Hongdong; Diao, Zongli; Liu, Wenhu
• Is Part Of: Journal of ultrasound in medicine. Volume 40:Number 11(2021)
• Page Start: 2497
• Page End: 2505
• Publication Date: 2021-01-23
• Subjects: hemodialysis -- long‐term effect -- microwave ablation (MWA) -- secondary hyperparathyroidism (SHPT); Ultrasonics in medicine -- Periodicals; Ultrasonics; Ultrasonography; Ultrasonics in medicine; Electronic journals; Periodicals; Periodicals; 616.07543
• DOI: 10.1002/jum.15638
• Languages: English
• ISSNs: 0278-4297

Abstract

Abstract : Objectives: A previous 12‐month study confirmed that microwave ablation (MWA) was effective for moderate secondary hyperparathyroidism (SHPT). A further analysis was performed in this study to evaluate the efficacy of MWA for moderate SHPT over an observational follow‐up period of up to 60 months. Methods: This was a retrospective cohort study of patients involved in a previous randomized controlled trial. Patients were divided into an MWA group (those who underwent MWA followed by drug therapy according to the patient's clinical situation) and a control group (those who received drug therapy only). The primary outcome was the composite endpoint. During the efficacy assessment phase, the two groups were compared in terms of the proportion of patients with intact parathyroid hormone (iPTH) levels <300 pg/ml and the differences in iPTH levels. Results: Twenty‐seven patients were included in this study: 13 in the MWA group and 14 in the control group. The median (interquartile range) follow‐up periods of the MWA and control groups were 58 (54–60) and 58 (49–60) months, respectively. The proportion of patients with iPTH levels <300 pg/ml in the MWA group was slightly higher than that in the control group (6/13 [46.2%] versus 2/14 [14.3%], respectively; p = .08). Furthermore, iPTH levels in the MWA group were lower than in the control group during the efficacy assessment phase (411 ± 299 pg/ml versus 516 ± 369 pg/ml, respectively; p <.01). Conclusions: MWA helped to contain the necessary iPTH levels in patients undergoing hemodialysis for moderate SHPT in a 60‐month timeframe.